Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Atrial Fibrillation
  • Atrial Flutter
  • Extrasystole, Atrial
  • Premature Atrial Complex
  • Premature Supraventricular Beats
  • Supraventricular Beat, Premature
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 65 years and 89 years
Gender
Both males and females

Description

Excessive supraventricular ectopic activities (ESVEA) are a common finding on long-term ECG recordings and have a connection to atrial cardiomyopathy, incident AF, stroke and mortality. Holter recording from 2018 preformed at Danderyd hospital will be screened in order to identify 125 recordings wit...

Excessive supraventricular ectopic activities (ESVEA) are a common finding on long-term ECG recordings and have a connection to atrial cardiomyopathy, incident AF, stroke and mortality. Holter recording from 2018 preformed at Danderyd hospital will be screened in order to identify 125 recordings with ESVEA, defined as at least 30 atrial ectopic beats/hour or a supraventricular run of at least 20 consecutive beats. Participants fulfilling eligibility criteria will be offered prolonged AF screening with continuous event recording (ELR). A matched control group (125 participants) without ESVEA will also be screened using same method. Cardiovascular data from medical records will also be collected in order to attain information regarding co-morbidities and being able to assess CHA2DS2-VASC score. Samples of blood will be collected at index time, after 21± 3 months for further analysis with the aim of identifying biomarkers for atrial fibrillation. During this two time periods transthoracic echocardiography will also be preformed. The study population will after 21± 3 months be subjected to renewed screening with ELR in order to examine the persistence of excessive supraventricular activity they will also preform a 24 hours ambulatory ECG (Holter). Four years after the completion of screening visits, data from patient records and information thorough telephone interview and/or data from Swedish Patient Register, Swedish Dispensed Drug Register will be collected

Tracking Information

NCT #
NCT04593498
Collaborators
Danderyd Hospital
Investigators
Not Provided